Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Lett. 2013 Oct 10;339(2):167-74. doi: 10.1016/j.canlet.2013.06.007. Epub 2013 Jun 18.

Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Author information

1
Cancer Center & Department of Internal Medicine, Division of Hematology and Medical Oncology & Biospecimen Laboratory, Loma Linda University, Loma Linda, CA 92350, United States.

Abstract

Survivin is a member of the inhibitor of apoptosis (IAP) family and has multifunctional properties that include aspects of proliferation, invasion and cell survival control. Survivin is a promising candidate for targeted cancer therapy as its expression is associated with poor clinical outcome, more aggressive clinico-pathologic features, and resistance to radiation and chemotherapy. In the present review the different properties of the Survivin splice variants are discussed and their activities correlated with different aspects of cancer cell biology, to include subcellular location. Special emphasis is placed on our current understanding of these Survivin splice variants influence on each other and on the phenotypic responses to therapy that they may control.

KEYWORDS:

Cancer; Splice variants; Survivin

PMID:
23791888
PMCID:
PMC3775917
DOI:
10.1016/j.canlet.2013.06.007
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center